Senti Biosciences is trading at $0.46 (+5.9%) amid ongoing volatility following the strategic divestiture of nearly all core pipeline assets to its largest shareholder, Celadon Partners.
- The move is framed as a pivot to survival due to a very limited cash runway, leaving the stock in a highly speculative position.
- Today’s modest price bounce appears to be driven by trading-related repricing rather than a fresh fundamental catalyst.